Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Bitcoin

S&P 500 Snub Deals Major Blow to MicroStrategy’s Bitcoin Ambitions

Robert Sasse by Robert Sasse
September 6, 2025
in Bitcoin, Blockchain, Crypto Stocks, S&P 500
0
Strategy Stock
0
SHARES
185
VIEWS
Share on FacebookShare on Twitter

In a move that stunned market participants, the committee overseeing the S&P Dow Jones Indices rejected MicroStrategy’s inclusion in the benchmark index this past Friday. The business intelligence firm, which recently rebranded as Strategy Inc., was passed over despite meeting all formal technical requirements for admission, including sufficient market capitalization and four consecutive profitable quarters. Instead, the coveted spots were awarded to Robinhood, AppLovin, and Emcor Group.

This exclusion represents a significant setback for the company. Inclusion would have compelled index-tracking funds to purchase its stock, and market experts had projected potential inflows of approximately $16 billion. The disappointment triggered an immediate sell-off, sending the company’s shares tumbling in after-hours trading.

A High-Stakes Strategy Faces Scrutiny

The decision is widely interpreted as a pointed critique of MicroStrategy’s singular focus. While the traditional financial market shows it a cold shoulder, the company continues to aggressively pursue its Bitcoin acquisition strategy. It now holds a colossal 214,400 Bitcoin, a stash valued at over $70 billion and the largest of any publicly traded corporation worldwide.

Should investors sell immediately? Or is it worth buying Strategy?

However, this massive expansion has come at a considerable cost. To fund its relentless Bitcoin purchases, MicroStrategy has systematically diluted existing shareholders through substantial secondary stock offerings. The company recently broke its own promise not to sell shares below a specific valuation multiple, underscoring the immense pressure to continue funding its crypto acquisitions.

Growing Disconnect Between Assets and Valuation

A particularly troubling trend for investors is the growing divergence between the company’s Bitcoin holdings and its stock performance. Although the Bitcoin treasury has more than doubled since the stock’s peak in late 2024, the share price has failed to keep pace. Consequently, each share now represents a significantly larger underlying Bitcoin value, a fact the market has so far refused to reward appropriately.

The S&P committee’s verdict appears to signal deep institutional skepticism regarding the sustainability of MicroStrategy’s high-risk, crypto-centric business model. The subsequent downward trend in the stock price following the news highlights a critical moment of reassessment for the pioneering Bitcoin corporate holder.

Ad

Strategy Stock: Buy or Sell?! New Strategy Analysis from February 7 delivers the answer:

The latest Strategy figures speak for themselves: Urgent action needed for Strategy investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Strategy: Buy or sell? Read more here...

Tags: Strategy
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Yirendai Stock
AI & Quantum Computing

Yirendai Charts a New Course with Tech-Driven Strategy

February 7, 2026
Diginex Stock
Blockchain

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
S&P 500 Stock
Market Commentary

US Benchmark Index Breaches Key Threshold Amid Tech and Jobs Concerns

February 6, 2026
Next Post
Eli Lilly Stock

Lilly's Oncology Breakthrough: Cancer Drug Designation Signals Pipeline Strength

OceanFirst Stock

OceanFirst's Strategic Moves Amid Mixed Financial Performance

US Physical Therapy Stock

Mixed Signals Emerge as US Physical Therapy Posts Record Results Amid Insider Sales

Recommended

10X Genomics Stock

10X Genomics Stock: A Study in Market Contradictions

5 months ago
Endava Stock

Endava Shares Continue Downward Spiral as Concerns Mount

4 months ago
Stratus Properties Stock

Stratus Properties Stock: A Turnaround Story Gains Momentum

5 months ago
MP Materials Stock

MP Materials Stock: A Market Conundrum

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Yirendai Charts a New Course with Tech-Driven Strategy

ServiceNow Shares Face Market Skepticism Despite Record Performance

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

A New Chapter for First Busey as CrossFirst Merger Finalizes

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Myers Industries Set to Report Full-Year and Q4 2025 Results

Trending

Allscripts Healthcare Stock
Analysis

Navigating a Pivotal Year: Veradigm’s Dual-Path Strategy for Stability and Growth

by Kennethcix
February 7, 2026
0

Formerly known as Allscripts Healthcare, Veradigm Inc. is navigating a critical period of corporate realignment with a...

Avanos Medical Stock

Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth

February 7, 2026
Guaranty Bancshares Stock

Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion

February 7, 2026
Yirendai Stock

Yirendai Charts a New Course with Tech-Driven Strategy

February 7, 2026
ServiceNow Stock

ServiceNow Shares Face Market Skepticism Despite Record Performance

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Navigating a Pivotal Year: Veradigm’s Dual-Path Strategy for Stability and Growth
  • Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth
  • Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com